(Q33658203)

28 July 2017

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse (English)

1 reference

28 July 2017

8

Razelle Kurzrock

1 reference

28 July 2017

6

Aung Naing

1 reference

28 July 2017

Rajul K Jain

1

1 reference

28 July 2017

J Jack Lee

2

1 reference

28 July 2017

David Hong

3

1 reference

28 July 2017

Maurie Markman

4

1 reference

28 July 2017

Jing Gong

5

1 reference

28 July 2017

Jennifer Wheler

7

1 reference

28 July 2017

language of work or name

English

0 references

publication date

9 February 2010

1 reference

28 July 2017

Clinical Cancer Research

1 reference

28 July 2017

16

1 reference

28 July 2017

1289-1297

1 reference

28 July 2017

4

1 reference

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?

28 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Risks and benefits associated with novel phase 1 oncology trial designs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

The needs of science vs the needs of patients: ethical concerns in cancer clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Clinical trial design for target specific anticancer agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Clinical trial design for target-based therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

The design of clinical trials for new molecularly targeted compounds: progress and new initiatives

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Ethical issues in the development of new agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Reporting results of cancer treatment

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Dose-response effect of adjuvant chemotherapy in breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Drug dosage and remission duration in childhood lymphocytic leukemia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Dose-response in the treatment of breast cancer: a critical review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Responses and toxic deaths in phase I clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Risks and benefits of phase 1 oncology trials, 1991 through 2002.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Phase I clinical trial design in cancer drug development.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Perceptions of cancer patients and their physicians involved in phase I trials.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Rethinking Risk-Benefit Assessment for Phase I Cancer Trials

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

On the nature and ethics of phase I clinical trials of cancer chemotherapies

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2822881

Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?

30 October 2018

1 reference

12 December 2020

Therapeutic response in phase I trials of antineoplastic agents

1 reference

12 December 2020

Response rates, duration of response, and dose response effects in phase I studies of antineoplastics

1 reference

12 December 2020

Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology

1 reference

12 December 2020

Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation

1 reference

12 December 2020

Risks and benefits of phase 1 oncology trials, revisited

1 reference

12 December 2020

New paradigm in dose-finding trials: patient-specific dosing and beyond phase I

1 reference

12 December 2020

Dose selection in phase I studies: why we should always go for the top

1 reference

12 December 2020

1 reference

12 December 2020

Dose selection in phase I studies: why we should always go for the most effective

1 reference

12 December 2020

Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients

1 reference

12 December 2020

10.1158/1078-0432.CCR-09-2684

Identifiers

DOI

1 reference

28 July 2017

1 reference

28 July 2017

1 reference